Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03921658 · ClinicalTrials.gov registry record

The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer

A clinical trial, sponsored by University of Minnesota.

Completed
Registry status
255
Enrollment target

NCT03921658 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 255 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03921658 has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
255 participants
Enrollment target

Study Summary

Cytomegalovirus (CMV), a widely prevalent virus in the general US population, has been shown to be associated with increased inflammation and mortality. Previous small pilot studies have demonstrated that latent CMV may be reactivated during chemotherapy in cancer patients, and may be associated with unfavorable cancer outcomes such as fatigue and increased mortality. The central research idea for this study, supported by previous preliminary data, is that CMV reactivation is an unrecognized complicating factor in the treatment of ovarian cancer that impacts patient outcomes. The overarching goals of this observational study are: * To assess how CMV infection is associated with ovarian cancer symptoms over the course of the disease and its treatment. * To describe the relationship between CMV reactivation in ovarian cancer patients, survival, fatigue, and other QOL outcomes, both cross-sectionally and longitudinally.

Trial Details

FieldValue
Enrollment Target 255 participants
Start Date 2019-10-22
Est. Completion 2024-04-02

Sponsor

University of Minnesota

966 total trials

What the Registry Record Tells You About NCT03921658

The ClinicalTrials.gov registry entry for NCT03921658 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT03921658 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03921658 about?

NCT03921658 is a clinical study titled "The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer". Cytomegalovirus (CMV), a widely prevalent virus in the general US population, has been shown to be associated with increased inflammation and mortality. Previous small pilot studies have demonstrated that latent CMV may be reactivated during chemotherapy in cancer patients, and may be associated wit...

What is the current status of trial NCT03921658?

This trial is currently completed. The enrollment target is 255 participants. The study started on 2019-10-22. Estimated completion is 2024-04-02.

Who is sponsoring clinical trial NCT03921658?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.